Managing Adverse Effects in Patients with HER2+ Breast Cancer

Opinion
Video

Harold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article
3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article